Gene polymorphism of CYP2C9 and VKORC1 and their relationships to the dosage of warfarin

doi:10.3969/j.issn.1673-8640.2014.06.014

Abstract

Abstract: Objective To investigate the relationship of cytochrome P450(CYP)2C9 and vitamin K epoxide reductase complex 1(VKORC1)genotypes with warfarin dosage, and to provide reference for the use of warfarin in Xuzhou city, Jiangsu, China. Methods A total of 100 Han-population healthy subjects and 200 patients with warfarin dosage were enrolled. CYP2C9 and VKORC1 genotypes were determined bypolymerase chain reaction and ligase detection reaction (PCR-LDR). Results There were 91 cases of CYP2C9 genotype with *1/*1 and 9 cases of CYP2C9 genotype with *1/*3 in healthy subjects. There were 17 cases of VKORC1 genotype with GA and 83 cases of VKORC1 genotype with AA. VKORC1(1639 G>A) genotype showed homozygote AA(168 cases), heterozygote GA (32 cases) and no GG in patients with warfarin dosageGYP2C9 genotype in 200 patients had 179 cases of *1/*1 and 21 cases of *1/*3, and there was no*2 mutation.Warfarin dosage in VKORC1(1639 G>A) in AA [ (2.59±0.83) mg/d] group was significantly lower than that in GA [(4.51±0.79)mg/d] group.Warfarin dosage in CYR2C9 genotype with *1/*9 [(3.01±1.12) mg/d] was higher than that with *1/*3 [(2.19±0.32)mg/L, P<0.05] . Conclusions CYP2C9 and VKORC1 genotype covariate therapy has the potential significance to improve the safety of warfarin use.

Key words: Cytochrome P450 2C9, Vitamin K epoxide reductase complex 1, Warfarin, Gene polymorphism

CLC Number:

Q503

NIU Guoping, WEI Yuanyuan. Gene polymorphism of CYP2C9 and VKORC1 and their relationships to the dosage of warfarin[J]. , 2014, 29(6): 635-639.

References

[1] 陈騉,王睿,文思远,等.用基因芯片技术测定健康人群P450 2C9基因多态性[J] .中国临床药理学杂志,2005,21(3):176-179.
[2] 李健,文思远,工睿,等.细胞色素P450 CYP2C9基因多态性对甲苯磺丁脲代谢动力学的影响[J] .药学学报,2005,40(8):695-699.
[3] 何震宇,孙丽敏,李月琴,等. 广东人群CYP2C9等位基因及基因型分布频率[J] .广东医学,2006,27(8):1131-1132.
[4] 唐和年,杜宇奎,张总刚.新疆维吾尔族健康人群细胞色素P450基因多态性研究[J] .中国药物与临床,2007,7(2):91-94.
[5] 梁欣,张亚同,程刚,等.基于连接酶反应检测硫唑嘌呤基因多态性及应用[J] .中国临床药理学与治疗学,2009,14(11):1281-1285.
[6] Yuan HY,Chen JJ, Lee MT,et al. A novel functional VK0RC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity [J] .Hum Mol Genet,2005,14(13):1745-1751.
[7] Veenstra DL, You JH, Rieder MJ, et al.Association of vitamin K epoxide reductase complex l (VKORC1 1) variants with warfarin dose in a Hong Kong Chinese patient population[J] .Pharmacogenet Genomics,2005,15(10):687-691.
[8] Rieder MJ,Reiner AP,Gage BF,et al.Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose[J] .N Engl J Med,2005,352(22):2285-2290.
[9] 庄文芳,吴婧,李莉. 华法林给药剂量预测模型的建立与应用[J] . 检验医学,2013,28(12):1157-1161.
[10] 吴炯,邬升超,郭玮,等. 华法林药物基因组学的发展及其临床应用前景[J] . 检验医学,2014,29(3):209-214.
[11] Sconce EA, Khan TI, Wynne H A, et al.The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen [J] . Blood,2005,106(7):2329-2333.
[12] Yoshizawa M,Hayashi H, Tashiro Y, et al. Effect of VKORC1-1639 G >A polymorphism,body weight,age,and serum albumin alterations on warfarin response in Japanese patients[J] .Thromb Res,2009,124(2):161-166.
[13] Chen LY, Eriksson N, Gwilliam R, et al. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing[J] . Blood,2005, 106(10):3673-3674.
[14] International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data[J] .N Engl J Med,2009,360(8):753-744.

[1]	PENG Shouning, DENG Weicong, FU Yanbo, WU Yanni. Relationship between KCNH2 and CACNA1C gene polymorphisms and cognitive function in patients with schizophrenia [J]. Laboratory Medicine, 2023, 38(8): 742-747.
[2]	ZHANG Xuming, YIN Weiming, GAO Jing. Correlation of UGT1A1 gene polymorphism with pregnancy complications and adverse pregnancy outcomes among gestational hypothyroidism patients in Shenzhen Bao'an area [J]. Laboratory Medicine, 2023, 38(7): 665-668.
[3]	LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239.
[4]	NIE Tian, RAN Zihan, JIN Lei. Research progress on the relationship between interleukin gene polymorphisms and gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 882-886.
[5]	WANG Lingling, REN Chunli. Correlation of MTHFR gene C677T polymorphism and blood lipid levels with GDM [J]. Laboratory Medicine, 2022, 37(6): 543-546.
[6]	WANG Shan, XU Minyi, WANG Wei, JIANG Mingming, LU Pei, XIONG Zhongbo, WANG Lei. Clinical value of MTHFR gene C677T polymorphism determination in patients with H-type hypertension [J]. Laboratory Medicine, 2022, 37(11): 1012-1016.
[7]	LIU Tingting, LIN Yuting, Mila , LI Xiaoqin. Correlation between serum IL-33 level and its gene polymorphism and the clinical outcome of HBV infection [J]. Laboratory Medicine, 2021, 36(11): 1101-1105.
[8]	ZHANG Qiang, LIN Jing, ZONG Xiaolong, SUN Guang, LIU Junfeng. Clinical evaluation of homemade Precil C3510 automatic coagulation analyzer for routine coagulation parameters [J]. Laboratory Medicine, 2020, 35(6): 601-608.
[9]	HONG Ping, WANG Peichang. Correlation between biochemical parameters and apolipoprotein E genotypes among inpatients with late-onset Alzheimer’s disease in Beijing [J]. Laboratory Medicine, 2020, 35(1): 1-5.
[10]	TANG Lin, ZHU Chenchen, XIAO Ye, WEI Bing, CAI Mei, ZHANG Xiaojing, TANG Zhenhua. Correlation between TSLP gene polymorphism and toddler atopic dermatitis [J]. Laboratory Medicine, 2019, 34(3): 249-252.
[11]	ZHANG Xiaomin, LIU Jing, GAO Shichao, YANG Tingting, WANG Peichang. Research progress of gene polymorphisms of ADH1B and ALDH2 and their related diseases [J]. Laboratory Medicine, 2019, 34(3): 271-275.
[12]	HAO Yexia, ZHENG Xuan, HU Yuanping, ZHANG Litao, YAN Xinsheng, CAO Shuzheng, WANG Zhang, ZHANG Zhenlu. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin anticoagulation strategy after cardiac valve replacement [J]. Laboratory Medicine, 2019, 34(2): 126-129.
[13]	ZHANG Shaohong, SHEN Xuebin. CYP2C19 gene polymorphism in the drug therapy of coronary heart disease [J]. Laboratory Medicine, 2018, 33(11): 979-982.
[14]	LIU Huifang. Relationship between apolipoprotein E gene polymorphism and blood lipid metabolism in hyperlipidemia patients [J]. Laboratory Medicine, 2018, 33(11): 987-990.
[15]	CHEN Dan, XU Ting, ZHANG Jiexin, ZHAO Hong, RONG Guodong, PAN Shiyang, WANG Fang, HUANG Peijun. Performance of real-time fluorescence PCR for the determination of CYP2C19 polymorphisms [J]. Laboratory Medicine, 2017, 32(9): 801-805.